SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Attention centers on the FDAs upcoming decision on Capricors deramiocel for Duchenne muscular dystrophy, with traders citing the amended upper-limb data, rare-disease policy discussions and recent launch-related hiring as reasons for optimism. Others caution that approval is uncertain given the prior negative review and continuing questions about the evidence.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Precigens strong quarterly results and rapid PAPZIMEOS commercial uptake are driving attention, with traders highlighting the companys return to profitability and potential for further growth. The upbeat reaction is accompanied by short-squeeze speculation and interest in upcoming PRGN-2009 data and European expansion.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A run to a 52-week high has traders positioning around the expected Q3 earnings report, with BRIUMVIs sales growth supporting optimism. Buyout rumors and heavy short interest are fueling squeeze speculation, though some traders see earnings expectationsnot a confirmed acquisitionas the main driver.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCaths post-TDAPA Medicare add-on could fall sharply after Q1 2027 has fueled concerns about pricing and CorMedix revenue amid a steep selloff. Traders dispute whether DaVitas preliminary outlook signals a broader reimbursement decline, pointing to CMSs published estimate, while others criticize management for not clarifying the potential impact.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs Phase 3 REGAL leukemia trial reached its prespecified 80th death event, triggering final analysis and putting the GPS survival readout at the center of discussion. Traders are divided between optimism about a strong result and concerns about the control arm and trial design, while shares have come under pressure ahead of the binary catalyst.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is under pressure after a steep decline, with traders focused on analyst price-target cuts and uncertainty ahead of its earnings report, as well as concerns about digital-ad growth. Bulls argue the selloff is disconnected from the companys profitability and growth, while bears warn of more downside if results or guidance disappoint; some also point to broader tech-market weakness.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A sharp technology and AI-linked selloffintensified by Intels weak outlook and concerns about returns on heavy AI investmentis driving attention to QQQ. Traders are split between warning of more downside and treating the drop as an oversold dip with potential for a rebound.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

SMH is under pressure amid a semiconductor and tech selloff, as traders question whether heavy AI infrastructure spending will generate adequate returns; weak Intel guidance and concerns about Amazons elevated capex are cited as contributing pressures. The community is divided between expecting a deeper unwind in the AI trade and seeing oversold conditions and technical support as possible grounds for a bounce.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Oktas strong quarterly results and raised outlook, alongside expectations that AI agents will increase demand for identity security, fueled a sharp rally. Traders are now debating whether the growth outlook justifies the valuation, with some taking profits or positioning for a pullback.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons stronger-than-expected third-quarter results, supported by growth in Eylea HD and Sanofi collaboration revenue from Dupixent, drove a sharp share-price gain. Traders largely celebrated the earnings beat and breakout, while some pointed to the upcoming cemdisiran decision as another potential catalyst.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

95-Year-Old Wall Street Law Firm Weil Gotshal Suddenly Lurches Towards Shutdown

95-Year-Old Wall Street Law Firm Weil Gotshal Suddenly Lurches Towards Shutdown

 Authored by Bill Pan via The Epoch Times,Weil, Gotshal & Manges is poised to close after a wave of senior partner departures and failed merger talks, bringing a potential end to a Wall Street law firm known...

APi (APG) Tops Q3 Earnings and Revenue Estimates

APi (APG) delivered earnings and revenue surprises of +6.38% and +6.90%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

AMN vs. TRI: Which Stock Is the Better Value Option?

Thomson Reuters Launches AI for Tax and Audit That Knows the Answer, and Why It's Right

Thomson Reuters Launches AI for Tax and Audit That Knows the Answer, and Why It's Right Thomson Reuters Launches AI for Tax and Audit That Knows the Answer, and Why It's RightPR NewswireTORONTO, Oct. 22, 2026 The next generation of CoCounsel Tax, Audit & Accounting plans the work, applies the...

Thomson Reuters Provides Supplemental Financial Information Following Close of Global Print Transaction

Thomson Reuters Provides Supplemental Financial Information Following Close of Global Print Transaction Thomson Reuters Provides Supplemental Financial Information Following Close of Global Print TransactionPR NewswireTORONTO, Oct. 19, 2026 TORONTO, Oct. 19, 2026 /PRNewswire/ -- As previously...

Thomson Reuters' AI Push Gains Steam: Is TRI Poised for Growth?

TRI is advancing AI products, raising its 2026 growth outlook and selling a majority stake in Global Print to sharpen its strategic focus.

Intuit's Lower DIY Tax Pricing: Will It Weigh on Revenue Growth?

INTU revamps its DIY tax strategy with lower-cost Credit Karma Tax options to win back customers, even as pricing shifts threaten to slow TurboTax growth in fiscal 2027.

Legal Work Crosses Borders. Now So Does CoCounsel Legal.

Legal Work Crosses Borders. Now So Does CoCounsel Legal. Legal Work Crosses Borders. Now So Does CoCounsel Legal.PR NewswireTORONTO, Oct. 14, 2026Thomson Reuters launches the next generation of CoCounsel Legal globally, adding cross-border legal research from more than 100 countries and territories...

Why Thomson Reuters Stock Topped the Market on Thursday

Key PointsThe company finalized the divestment of a majority stake in its printing unit...

Can 10% Core Growth Keep Thomson Reuters' Momentum Intact?

TRI's Big 3 businesses deliver 10% organic growth, reinforcing their role in driving revenues as recurring sales expand.

Thomson Reuters Corp. engages in the provision of news and information for professional markets. It operates through the following segments: Legal Professionals, Corporates, Tax and Accounting Professionals, Reuters News, and Global Print. The Legal Professionals segment provides research and workflow products to law firms and government. The Corporates segment serves corporate customers with full suite of content-enabled technology solutions for in-house legal, tax, regulatory, compliance, and information technology professionals. The Tax and Accounting Professionals segment offers research and workflow products focusing on intuitive tax offerings and automating tax workflows to tax, accounting, and audit professional in accounting firms. The Reuters News segment supplies business, financial, national, and international news to professionals via desktop terminals. The Global Print segment offers legal and tax information primarily in print format to customers around the world. The company was founded in 1799 and is headquartered in Toronto, Canada.

Thomson-Reuters Corp

Why DOCU, TRI Stocks Slid Over 3% After Google Cloud’s Latest AI Release

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>Thomson Reuters and DocuSign shares fell 4% and 3.2%, respectively, amid fears of AI disruption.</li><li>Anthropic’s legal AI launch in February triggered an 18% plunge in Thomson Reuters shares.</li><li>Google’s latest move is another test for the SaaS sector, even as software stocks have staged periods of recovery this month.</li></ul>Alphabet, Inc.-owned Google’s latest artificial-intelligence&nbsp;unveiling is giving investors another reason to worry about the threat AI poses to traditional software, with shares of Thomson Reuters and DocuSign falling Tuesday.Google Cloud CEO Thomas Kurian announced Gemini Enterprise for Legal, a version of Google’s enterprise AI platform designed for law firms and corporate legal teams.&nbsp;The offering can connect with legal data and workflow systems and use AI agents for tasks including research, document analysis and contract-related work. Google also launched a parallel Gemini Enterprise offering for financial services.&nbsp;&nbsp;<h2 class="st-heading-2">Thomson Reuters, DocuSign Hit&nbsp;</h2>Shares of Thomson Reuters Corp., which has a sizable legal services business through its properties Westlaw, Practical Law, and CoCounsel, fell 4% on Tuesday. Shares of DocuSign, which provides software for electronic signatures and managing digital agreements and contracts, dropped 3.2%.The moves underscore a broader concern that has repeatedly hit software stocks this year: AI companies are moving from offering general-purpose chatbots to&nbsp;taking on specific, high-value software workflows.Thomson Reuters launched Thomson 1.0, its own open-weight legal-focused large language model, just a day earlier. Google lists DocuSign among the connectors that can be integrated into Gemini Enterprise for Legal, highlighting how AI platforms could increasingly sit on top of — rather than simply replace — existing software workflows.&nbsp;&nbsp;Anthropic’s launch of legal-focused AI tools in February triggered a much sharper selloff across legal and information-services stocks. Thomson Reuters plunged as much as 18% at the time.<h2 class="st-heading-2">Saas Stocks Rebound, But AI Fears Remain</h2>That makes Google’s latest move another test for the SaaS sector, even as software stocks have staged a recovery this month. Investors are increasingly separating AI beneficiaries from companies whose core products could be automated or bundled into AI platforms.The result is a widening gap between SaaS winners and losers as Wall Street reassesses which software businesses have durable competitive moats.In August, Paycom Software and Palantir Technologies returned over 40%, emerging as top software gainers in the S&amp;P 500. Trade Desk and AppLovin Corp are the biggest losers, with 27% and 22% drops respectively.<a href="https://stocktwits.com/symbol/IGV">The iShares Expanded Tech-Software Sector ETF (IGV)</a>, seen as a benchmark for the software sector, rose 7.7% so far in August but remains 3.6% lower for the year.On Stocktwits, the retail sentiment was ‘neutral’ for TRI and DOCU and ‘extremely bearish’ for GOOGL and IGV on Tuesday.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/intuit-ceo-admits-pricing-is-driving-turbo-tax-customers-away-says-low-cost-fix-coming-as-stock-extends-tumble-overnight/cZYNiVQRJoq">Intuit CEO Admits Pricing Is Driving TurboTax Customers Away, Says Low-Cost Fix Coming As Stock Extends Tumble Overnight</a>&nbsp;

Businessman working on laptop with artificial intelligence law icons showing regulation, ethics and compliance standard. (Source: Getty Images)

Google launched Gemini Enterprise for Legal, targeting research, document analysis, and contract work.

DocuSign Inc

Alphabet Inc - Ordinary Shares - Class C

Alphabet Inc Class A

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$118.25
Prev Close	$116.35
Open	$119.73
Dividend Yield	1.81%
50-Day Moving Average	$104.57
Beta	0.42
Avg. Volume	1.55M
PE Ratio	31.18

52-Week High	$157.67
52-Week Low	$76.28
Market Capitalization	$50.41B
EPS (Annual)	$3.34
Price to Book	4.57
Revenue Per Employee	$275,867.16

Feed

News

Sentiment

Earnings

Fundamentals

Info

TRI Fundamentals